Positive response for Oncolytics’ cancer virus program spurs share spike

John Carroll

Shares of Canada's Oncolytics surged again this morning after the biotech reported out a final analysis on its tumor Reolysin, showing a 92% rate among a small group of 25 patients enrolled in a Phase II study.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS